19th January 2023
Can Human Milk Oligosaccharides Modulate the Allergic Response and Improve the Management of Cow’s Milk Protein Allergy?
Human milk oligosaccharides (HMOs) support the development of the infant microbiome and have immune benefits in the management of cow’s milk protein allergy (CMPA).
20th December 2022
Recent Advances in the Management of Gastrointestinal Disease
Interdisciplinary sessions at the recent United European Gastroenterology (UEG) Week, held in Vienna, Austria, from 8th to 11th October 2022, covered new approaches to the diagnosis and treatment of gastrointestinal and hepatic disorders, with a focus on advances in the non-invasive management of these diseases. Abstract-based and poster sessions presented original research from Europe and other parts of the world.
19th December 2022
Nothing About Me Without Me: Shared Decision-Making in Chronic Hepatitis B
Hepatitis B affects more than 296 million people worldwide, according to the World Health Organization (WHO). More than 1.5 million new infections occur each year, despite the availability of safe and effective vaccines.
8th December 2022
Overview of Obstructive Hypertrophic Cardiomyopathy
Obstructive HCM is a condition in which the heart has thickened walls that are not caused by blockage of the heart valves or by very high blood pressure. For the majority of patients, the cause of their disease has a genetic basis and is hereditary. A genetic test can diagnose HCM in some patients, but the results are inconclusive in others.
8th December 2022
Management of Children with Swallowing Problems: New Advances in Paediatric Thickeners
Dysphagia is defined as “any disruption to the swallow sequence that results in compromise to the safety, efficiency, or adequacy of nutritional intake.” Dysphagia may have an oropharyngeal or oesophageal cause, resulting in delayed transit of liquids or solid food from the mouth to the stomach.
8th December 2022
Tailoring Motor Fluctuation Treatment: Beyond Levodopa Dose Adjustment
Fox emphasised that PD is one of the fastest-growing neurological disorders. Disability and deaths related to it have more than doubled from 1990–2015. Its prevalence is expected to grow exponentially by 2040, affecting approximately 12.9 million individuals worldwide.
5th December 2022
Targeting Fibroblast Growth Factor Receptor Alterations in Cholangiocarcinoma and Other Solid Tumours: A New Frontier in Personalised Medicine
Cholangiocarcinoma (CCA) is a cancer of the bile duct with poor prognosis and increasing incidence. Filippo de Braud gave an overview of CCA and its classification and highlighted key unmet needs in both diagnosis and treatment. Juan Valle explained that intrahepatic CCA (iCCA) accounts for 11% of the entire cancer of unknown primary (CUP) population, as well as 33% of patients with liver-inclusive disease.
28th November 2022
Proactive Risk Management: A Novel Approach to Embedding Oral Corticosteroid Stewardship into Asthma Care
The continued inclusion of oral corticosteroids (OCS) in treatment guidelines, as well as the accessibility, familiarity, and relatively low cost of this therapeutic option compared with newer alternatives, has contributed to an ongoing overreliance on OCS treatments in severe asthma. This overuse continues despite accumulating evidence to demonstrate the detrimental long-term effects associated with even a short-term, low-dose course of OCS in this patient population.